Page 5 - Preclinical Data News Today

The latest news on the science of Biotechnology, from the best sources of Biotechnology news. Get the latest Biotechnology news now.

- Progressionsfreies Überleben (PFS) unter Derazantinib-Monotherapie auf acht Monate verlängert Basel, 17. September 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute die Veröffentlichung

COPENHAGEN, Denmark, June 03, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company developing AI-driven immunotherapies and vaccines to improve the lives of patients with cancer and infectious diseases, announced today new preclinical data from its Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses (AICoV) program. The AICoV program aims to potentially develop the next generation of corona virus vaccines, utilizing RAVEN, Evaxion

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating functional AAT protein Wave’s program in alpha-1 antitrypsin deficiency aims to correct the single base mutation in mRNA derived from the SERPINA1 Z allele, thereby addressing both lung and liver manifestations of the disease CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences L...

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases associated with cognitive impairment CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced the publication of preclinical data of CY6463 in Frontiers in Pharmacology. Cyclerion is developing CY6463, an oral, first-in-class, central nervous system (...

Immunicum AB Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting Press Release 03 May 2021 Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting Immunicum AB (publ; IMMU.ST) announced today the publication of two abstracts for oral presentations covering precl...

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Toxin Conjugates (BTCs) and tumor targeted immune cell agonists (TICAs) Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones First clinical trial site outside of the United States opened in ongoing Phase I/II trial of BT8009 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pionee...

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results - Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic - - Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs - - Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence and clinical activity - - A PRGN-3006 UltraCAR-T patient...

Celltrion Healthcare Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59 Wednesday, January 13, 2021 3:52PM IST (10:22AM GMT)     CT-P59 (40mg/kg) treated patients reported reduced progression rates to severe COVID-19 by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over CT-P59 (40mg/kg) treated patients reported a significantly shortened time to cl...